Designing of heterocyclic compounds as promising VEGFR2 tyrosine kinase inhibitors: An Insilico analysis
Abstract
Cancer is the most dangerous disease a human race battles with. Due to which, it is necessity of medicinal chemist to evaluate possible scenario to fight against this disease. The heterocyclic compounds has shown to possess intrinsic diversity and several physicochemical properties. Thus investigation of newer and potential compounds for their activity to resist several malignancies. The present study aims to derivatize four different heterocyclic compounds. The number of members present in the ring has importance in heterocyclic compounds. Thus the six-member ring containing pyrimidine, six-member ring fused with five member ring in indole, bi-penta membered ring containing thiadiazole and one six membered and a penta membered ring containing triazoles have been used in the present study. In the search of potential anti-cancer drugs, several molecules were evaluated and checked for their potency to interact with a cancer target enzyme Vascular endothelial growth factor receptor 2 (VEGFR2). This study involves detailed in-silico analysis of several compounds and indicates compounds having potential ability to resist this enzymes and hence the anti-cancer agent.
Keywords:
: Heterocyclic compounds;, Thiadiazole;, VEGFR2, Anti-cancer drugs;, target enzyme;DOI
https://doi.org/10.25004/IJPSDR.2021.130612References
Salem MS, Sakr SI, El‐Senousy WM, Madkour HM. Synthesis, antibacterial, and antiviral evaluation of new heterocycles containing the pyridine moiety. Archiv der Pharmazie 2013; 346(10):766-773.
El-Salam A, Nasser M, Mostafa MS, Ahmed GA, Alothman OY. Synthesis and antimicrobial activities of some new heterocyclic compounds based on 6-chloropyridazine-3 (2H)-thione. Journal of Chemistry 2013; 1-8.
Cao X, Sun Z, Cao Y, Wang R, Cai T, Chu W, Hu W, Yang Y. Design, synthesis, and structure–activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility. Journal of medicinal chemistry 2014; 57(9):3687- 3706.
El-Sawy ER, Mandour AH, El-Hallouty SM, Shaker KH, Abo-Salem HM. Synthesis, antimicrobial and anticancer activities of some new N-methylsulphonyl and N-benzenesulphonyl-3-indolyl heterocycles: 1st Cancer Update. Arabian Journal of Chemistry 2013; 6(1):67-78.
Chen Y, Yu K, Tan NY, Qiu RH, Liu W, Luo NL, Tong L, Au CT, Luo ZQ, Yin SF. Synthesis, characterization and anti-proliferative activity of heterocyclic hypervalent organoantimony compounds. European Journal of Medicinal Chemistry 2014; 79:391-398.
Mabkhot YN, Kheder NA, Barakat A, Choudhary MI, Yousuf S, Frey W. Synthesis, antimicrobial, anti-cancer and molecular docking of two novel hitherto unreported thiophenes. RSC advances 2016; 6(68):63724-63729.
Eicher T, Hauptmann S, Speicher A. The chemistry of heterocycles: structures, reactions, synthesis, and applications. John Wiley & Sons 2013:1-4.
Selvam TP, James CR, Dniandev PV, Valzita SK. A mini review of pyrimidine and fused pyrimidine marketed drugs. Research in Pharmacy 2015; 2(4).
Lakhdar S, Westermaier M, Terrier F, Goumont R, Boubaker T, Ofial AR, Mayr H. Nucleophilic reactivities of indoles. The Journal of organic chemistry 2006; 71(24):9088-9095.
Vitaku E, Smith DT, Njardarson JT. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among us FDA approved pharmaceuticals: miniperspective. Journal of medicinal chemistry 2014; 57(24):10257-10274.
Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Research 1990; 50(1):2-9.
Bell FW, Cantrell AS, Hoegberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin Jr JM. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. Journal of medicinal chemistry 1995; 38(25):4929-4936.
Liu XH, Shi YX, Ma Y, Zhang CY, Dong WL, Pan L, Wang BL, Li BJ, Li ZM. Synthesis, antifungal activities and 3D-QSAR study of N-(5- substituted-1, 3, 4-thiadiazol-2-yl) cyclopropanecarboxamides. European journal of medicinal chemistry 2009; 44(7):2782- 2786.
Rudolph J, Theis H, Hanke R, Endermann R, Johannsen L, Geschke FU. seco-Cyclothialidines: new concise synthesis, inhibitory activity toward bacterial and human DNA topoisomerases, and antibacterial properties. Journal of medicinal chemistry 2001; 44(4):619-626.
Carter JS, Kramer S, Talley JJ, Penning T, Collins P, Graneto MJ, Seibert K, Koboldt CM, Masferrer J, Zweifel B. Synthesis and activity of sulfonamide-substituted 4, 5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters 1999; (8):1171-1174.
Cejudo R, Alzuet G, Gonzalez-Alvarez M, García-Gimenez JL, Borrás J, Liu-González M. DNA cleavage reaction induced by dimeric copper (II) complexes of N-substituted thiazole sulfonamides. Journal of inorganic biochemistry 2006; 100(1):70-79.
Bolos CA, Papazisis KT, Kortsaris AH, Voyatzi S, Zambouli D, Kyriakidis DA. Antiproliferative activity of mixed-ligand dien-Cu (II) complexes with thiazole, thiazoline and imidazole derivatives. Journal of inorganic biochemistry 2002; 88(1):25-36.
El-Subbagh HI, Al-Obaid AM. 2, 4-Disubstituted thiazoles II. A novel class of antitumor agents, synthesis and biological evaluation. European journal of medicinal chemistry 1996; 31(12):1017-1021.
Donnem T, Al‐Shibli K, Andersen S, Al‐Saad S, Busund LT, Bremnes RM. Combination of low vascular endothelial growth factor A (VEGF‐A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 2010; 116(18):4318-4325.
Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Human pathology 2008; 39(12):1835-1843.
Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, Horning S, Sehn LH, Farinha P, Briones J, Lossos IS. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R‐CHOP). British journal of haematology 2010; 148(2):235-244.
Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Human pathology 2010; 41(3):375-384.
Kaur R, Kaur P, Sharma S, Singh G, Mehndiratta S, MS Bedi P, Nepali K. Anti-cancer pyrimidines in diverse scaffolds: a review of patent literature. Recent patents on anti-cancer drug discovery 2015; 10(1):23-71.
Dadashpour S, Emami S. Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms. European journal of medicinal chemistry 2018; 150:9-29.
Jain S, Pattnaik S, Pathak K, Kumar S, Pathak D, Jain S, Vaidya A. Anticancer potential of thiazole derivatives: A retrospective review. Mini reviews in medicinal chemistry 2018; 18(8):640-655.
Chou JY, Lai SY, Pan SL, Jow GM, Chern JW, Guh JH. Investigation of anticancer mechanism of thiadiazole-based compound in human non-small cell lung cancer A549 cells. Biochemical pharmacology 2003; 66(1):115-124.
Kumar D, Kumar NM, Chang KH, Shah K. Synthesis and anticancer activity of 5-(3-indolyl)-1, 3, 4-thiadiazoles. European journal of medicinal chemistry 2010; 45(10):4664-4668.
Release S. 2: Maestro, Schrödinger, LLC, New York, NY, 2017. Received: February. 2016; 21:2018.
Lagorce D, Bouslama L, Becot J, Miteva MA, Villoutreix BO. FAF-Drugs4: free ADME-tox filtering computations for chemical biology and early stages drug discovery. Bioinformatics 2017; 33(22):3658- 3660.
Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of medicinal chemistry 2010; 53(7):2719-2740.
McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proceedings of the National Academy of Sciences 2012; 109(45):18281-18289.
Rose PW, Bi C, Bluhm WF, Christie CH, Dimitropoulos D, Dutta S, Green RK, Goodsell DS, Prlić A, Quesada M, Quinn GB. The RCSB Protein Data Bank: new resources for research and education. Nucleic acids research 2012; 41(D1):D475-D482.
Guex N, Peitsch MC. SWISS‐MODEL and the Swiss‐Pdb Viewer: an environment for comparative protein modeling. Electrophoresis 1997; 18(15):2714-23.
Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. Journal of computational chemistry 2005; 26(16):1701-18.
Schmid N, Eichenberger AP, Choutko A, Riniker S, Winger M, Mark AE, van Gunsteren WF. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. European biophysics journal 2011; 40(7):843-56.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. Journal of computational chemistry 2010; 31(2):455-461.
Schüttelkopf AW, Van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein–ligand complexes. Acta Crystallographica Section D: Biological Crystallography 2004; 60(8):1355-1363.
Kumari R, Kumar R, Open Source Drug Discovery Consortium, Lynn A. g_mmpbsa A GROMACS tool for high-throughput MM-PBSA calculations. Journal of chemical information and modeling. 2014 Jul 28;54(7):1951-1962.
Published
Abstract Display: 547 
PDF Downloads: 456 
